/PRNewswire/ Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,.
The use of bacterial metabolites as a biomarker for Parkinson disease could help confirm diagnosis and inform microbiota-modifying treatment approaches.